MDMA for PTSD and beyond: a new paradigm brings hope
Scott Shannon,Jamarie Geller
DOI: https://doi.org/10.3389/fnhum.2024.1475013
IF: 3.473
2024-12-12
Frontiers in Human Neuroscience
Abstract:Introduction We are experiencing a mental health crisis of unprecedented proportions. Over the last two decades this crisis grew from a perfect storm of rising insurance deductibles, escalating social stressors, the COVID-19 pandemic, and a critical workforce deficiency. Perhaps no mental health arena has a greater shortfall of effective treatment options than Post-traumatic Stress Disorder (PTSD) as the last new treatment was approved by the FDA 24 years ago (Hamner and Davis, 2024). Inadequate funding for research efforts and public resources available to expandservices may in part stem from the inordinate prevalence of PTSD among women anddisadvantaged populations. Women experience PTSD at two to three times the rate found inmen (US Department of Veterans Affairs, 2023), and these rates are also significantly higheramong African Americans, Latinos, Native Americans, and the homeless (Tortella-Feliu et al.,2019; Kwon et al., 2024; Armoon et al., 2019; Reyes, et al., 2019). Neighborhood poverty alsopredicts the development of PTSD following a traumatic event (Ravi, et al, 2023). Our traumaburden is unevenly distributed across society.Trauma is unfortunately quite common. The National Center for PTSD estimates that over 13 million people in the US suffer from PTSD with 5% of our population diagnosed in any given year (US Department of Veterans Affairs, 2023). The annual cost in the US has been estimated at 19,630) in 2018 (Davis et al., 2022). Veterans as a group report high levels of trauma. According to the National Center for PTSD, 23% of veterans accessing the Veterans Administration services are diagnosed with PTSD (USDepartment of Veterans Affairs, 2023). Suicide, often linked to trauma and PTSD, has nowbecome the leading cause of death for those serving in our Armed Forces (Kaplansky andToussaint, 2024). For our society, the human suffering from trauma is immense and undeniable. Yet, our current treatments are inadequate (Smith et al, 2024). Trauma-focused psychological therapies (TFPT) are the best-evidenced interventions for PTSD, and they are typically first line (Schrader and Ross, 2021). However, only about 50% of patients complete a course of treatment, and the response rates for those who do are roughly 50% (Schottenbauer et al., 2008). TFPTs are often not used by clinicians (Kline et al., 2001) due to fear of retraumatizing, dislike of manualized, rigid therapies and concern over symptom exacerbation (Finch et al, 2020). Even when high-quality TFPT is offered, patients often refuse to even consider this option because facing trauma in this way is extremely painful (Schottenbauer et al., 2008). Our indicated medications, such as sertraline and paroxetine which were first approved in the early 1990s, are minimally effective as evidenced by small effect size (0.28 and 0.23, respectively) (Hoskins et al, 2015; Hoskins et al., 2021) and often burdened with side effects. The need for innovation in PTSD care feels critical. MDMA and the Psychedelic Framework MDMA represents our best hope for innovation in the treatment of PTSD in over a generation. The current application to the FDA for MDMA-assisted psychotherapy (MDMA-AP) is the first time that the FDA has considered this linkage of psychotherapy to a medication (DeBattista and Schatzberg, 2024). This combination serves as the core of the psychedelic framework. This framework has three components: container, catalyst and carrier (Shannon, 2023). The container is the psychotherapeutic model of support, safety and rapport as well as attention to set and setting. This creates the atmosphere of trust that is critical to work with traumatized patients. The catalyst is the psychedelic medication itself. This agent alters consciousness and the flow of information within it. This improves access to memories and feelings including traumatic material. Mechanistically, MDMA, psilocybin, and ketamine are all quite different, and their distinctive neurochemical properties continue to be elaborated. However, they all ultimately induce an altered awareness and enhanced processing of contents held in the psyche. Finally, there is the carrier. This includes the use of curated music delivered by headphones, and eyeshades designed to drive the experience inward for therapeutic benefit. Without the carrier, the experience may be externally focused, and of little consequence other than amusement or distraction. While music is commonly considered a part of set and setting, in the psychedelic framework of psychotherapy it can also be considered a tool (along with eye shades and headphones) designed to support the inward focus of attention. Music does contribute to context, but it also plays a larger role in the inward nature of the experience by reducing cognitive hierarchy. This synergistic effect with psychedelics allows for greater flexibility in thought and perception -Abstract Truncated-
psychology,neurosciences